上皮性卵巢肿瘤组织中PSMD10、Ki67的表达及其临床病理意义

Expression of PSMD10 and Ki67 in epithelial ovarian carcinoma and its clinicopathological significance

目的研究上皮性卵巢肿瘤组织中PSMD10和Ki67的表达及其临床病理意义。方法通过免疫组化SP法检测21例卵巢良性肿瘤、31例卵巢交界性肿瘤、156例卵巢癌组织中PSMD10和Ki67的表达情况。结果 PSMD10和Ki67在卵巢癌组织中的阳性表达率显著高于卵巢交界性肿瘤和良性肿瘤(P<0.05)。PSMD10在卵巢癌组织中的阳性表达率与患者的年龄、病理类型无统计学意义(P>0.05),而与临床分期、病理分级和残留肿瘤直径有统计学意义(P<0.05)。卵巢癌组织中PSMD10和Ki67的表达呈正相关(P<0.01)。结论 PSMD10和Ki67在上皮性卵巢癌的发生、发展中起到了重要的协同作用,可作为判断卵巢癌恶性程度、病情进展的重要指标,联合检测用于指导临床诊断。

Objective The objective of this study was to investigate the expression of PSMD10 and Ki67 in epithelial ovarian tumors and its clinicopathological significance. Methods Immunohistochemical method was used to detect the expression of PSMD10 and Ki67 in 21 cases of ovarian benign tumor,31 cases of ovarian borde-rline tumor and 156 cases of ovarian cancer. Results The positive expression rate of PSMD10 and Ki67 in ovari-an cancer was significantly higher than those of ovarian l〉orderline and benign tumor（ P 〈0. 05 ）. The positive ex-pression rate of PSMD10 in ovarian cancer tissues was not different from others groups（ P 〉0. 05）. There was sig- nificant different the positive expression rate of PSMD10 from clinical stage, pathological grade and residual tumor diameter（ P 〈 0. 05）. There was a positive correlation between the expression of PSMD10 and Ki67 in ovarian cancer（ P 〈0. 01 ）. Conclusion PSMD10 and Ki67 play an important synergistic role in the carcinogenesis and progression of epithelial ovarian cancer. It can be used as an important index to judge the degree of malignancy and progression of ovarian cancer. Joint testing PSMD10 and Ki67 are used to guide the clinical diagnosis.